Physician profile
Russell E Jones
NPI 1336351865
$7,086.81
in general payments reported to CMS, 2019-2025
29 companies · $755 in 2025
The $755 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,313 · 2020: $345 · 2021: $1,069 · 2022: $1,162 · 2023: $938 · 2024: $1,505 · 2025: $755.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,996 · Travel and Lodging: $187 · Education: $16.03.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,995.53 |
| Travel and Lodging | $186.67 |
| Education | $16.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $2,193.45 | 2019-2025 | Avvigo Guidance System, General - Vascular Access, Interlock |
| Shockwave Medical, INC | $541.15 | 2021-2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Astrazeneca Pharmaceuticals LP | $517.66 | 2019-2025 | Farxiga |
| E.R. Squibb & Sons, L.L.C. | $490.55 | 2019-2025 | Eliquis, Camzyos |
| Janssen Pharmaceuticals, INC | $428.31 | 2019-2024 | Xarelto |
| Abiomed | $371.87 | 2022-2025 | Impella |
| Amgen INC. | $345.41 | 2019-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $266.58 | 2019-2023 | |
| Penumbra, INC. | $222.78 | 2024 | Indigo System |
| Pfizer INC. | $198.84 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $188.85 | 2019-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $177.66 | 2022-2025 | Verquvo |
| Abbott Laboratories | $163.92 | 2019-2020 | |
| Impulse Dynamics (USA) INC. | $132.67 | 2022 | |
| Siemens Medical Solutions USA, INC. | $110.28 | 2021 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $100.25 | 2019 | |
| Teleflex LLC | $98.03 | 2023 | Guideliner |
| Kestra Medical Technology Services, INC. | $94.32 | 2025 | Assure Wcd |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $90.87 | 2025 | Lifevest |
| Cardiovascular Systems INC. | $80.81 | 2019-2021 | |
| Gilead Sciences, INC. | $62.93 | 2019 | |
| Esperion Therapeutics, INC. | $44.83 | 2025 | Nexletol |
| Bayer Healthcare Pharmaceuticals INC. | $44.75 | 2024-2025 | |
| Daiichi Sankyo INC. | $28.72 | 2023 | Injectafer |
| Sanofi-Aventis U.S. LLC | $20.57 | 2019 | |
| Inspire Medical Systems, INC. | $18.04 | 2025 | Inspire |
| Philips North America LLC | $17.96 | 2024 | (Cm9) Amb Mon & Diag Und |
| Scpharmaceuticals INC. | $17.94 | 2023 | |
| Angiodynamics, INC. | $16.81 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Russell Jones listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.